Panzyga (Human Normal Immunoglobulin)

Human Normal Immunoglobulin, the active ingredient in Panzyga, is an Immunoglobulin presented as a 10% solution for intravenous use. It replaces deficient antibodies and is used in primary immunodeficiency disorders and certain secondary immune deficiencies. GNH USA supplies Panzyga as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

GNH USA supplies Panzyga as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

Panzyga is an immunoglobulin replacement therapy that addresses antibody deficiencies across several clinical settings.

- Primary immunodeficiency disease (PID): provides supplemental IgG to reduce infection frequency. - Secondary immunodeficiency (e.g., chronic lymphocytic leukemia CLL): supplies IgG to support immune function. - Post‑transplant immune support: helps maintain protective antibody levels after hematopoietic stem‑cell transplantation. - Primary antibody deficiency with bronchiectasis: lowers risk of pulmonary exacerbations. - Immunodeficiency associated with protein‑losing enteropathy.

Panzyga may cause a range of adverse reactions, most of which are mild to moderate and resolve after infusion.

Common Side Effects: - Headache - Fatigue - Chills - Nausea - Mild fever - Injection site erythema

Serious or Rare Side Effects: - Anaphylaxis - Acute hemolytic transfusion reaction - Thromboembolic events - Renal impairment - Aseptic meningitis - Severe hypotension

Before using Panzyga, clinicians should consider several safety measures.

- Renal function monitoring: assess baseline creatinine and adjust infusion rate if needed. - Cardiovascular status: evaluate for heart failure risk before rapid infusions. - History of thrombotic events: use caution and monitor coagulation parameters. - Concomitant immunoglobulin products: avoid overlapping therapy to reduce overload risk. - Infusion reactions: be prepared to manage hypersensitivity during administration. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Panzyga can interact with other agents that affect immune function or blood viscosity.

Major Interactions (Avoid): - Concurrent high‑dose IVIG or plasma products: may cause hyperviscosity. - Rituximab: can increase risk of severe infusion reactions.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may require dose adjustment due to altered coagulation. - Corticosteroids: may mask early signs of infusion‑related adverse events. - Live vaccines: reduced efficacy; schedule vaccinations appropriately. - Diuretics: monitor fluid balance during infusion. - ACE inhibitors: watch for additive hypotensive effects.